New Price Headwinds Swirl In India
Executive Summary
Fresh efforts to rein in drug prices may be on the cards in India, as the government evaluates linking prices of all medicines to a wholesale price index. Industry anticipates "major disruption" if the proposal goes through.
You may also be interested in...
India’s Pricing Authority Head Shunted Out?
India’s firebrand pharma pricing authority chief has been transferred out amid sharply polarized views on either side of the debate around his controversial stint.
Negative WPI Set To Trigger Price Cuts In India?
The going has generally been tough for pharmaceutical firms in India this past year, stretched by volatility in certain emerging markets and plant woes, but the industry there should probably steel itself for yet more pain on its home turf.
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.